Want to see VRPX full AI Analyst Report?
Virpax Pharmaceuticals (VRPX) AI Stock Analysis
Virpax Pharmaceuticals
(Other OTC:VRPX)
Virpax Pharmaceuticals receives a very low overall score of 37, reflecting severe financial distress and a bearish technical picture. The company has no revenue, massive losses, negative equity, and is burning cash at an unsustainable rate. The stock price is in a steep downtrend with no signs of reversal. Valuation metrics are irrelevant due to the absence of profits. Investors should be aware of the extremely high risk associated with this stock.
Virpax Pharmaceuticals (VRPX) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $994
- Dividend Yield
- ―
- Average Volume (3M)
- 785
- Price to Earnings (P/E)
- 0.0
- Beta (1Y)
- -18790.74
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- US
- Employees
- 2
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Virpax Pharmaceuticals Business Overview & Revenue Model
Company Description
Virpax Pharmaceuticals, Inc. operates as a preclinical-stage pharmaceutical enterprise, dedicated to pioneering diverse drug-delivery systems and novel drug-releasing technologies. Its core focus lies in developing advanced, non-opioid and non-addict...
How the Company Makes Money
Virpax Pharmaceuticals makes money through the development and commercialization of its proprietary drug delivery systems and pharmaceutical products. The company's revenue model includes licensing agreements with other pharmaceutical companies and p...
Virpax Pharmaceuticals Financial Statement Overview
Summary
Virpax Pharmaceuticals has no revenue, reported a $12.1 billion net loss, negative stockholders' equity, and severe cash burn. The absence of debt is a minor positive but does not offset the existential risks. Financial health is extremely weak.
Income Statement
1Very NegativeBalance Sheet
1Very NegativeCash Flow
1Very Negative| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Mar 2022 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -3.36M | -11.96M | -2.25M | -3.31M | 62.26K | 4,000 |
| Net Income | -12.07M | -12.07M | -15.19M | -21.46M | -12.15M | -4.49M |
Balance Sheet | ||||||
| Total Assets | 1.56M | 1.56M | 9.63M | 19.67M | 39.57M | 465.41K |
| Cash, Cash Equivalents and Short-Term Investments | 1.51M | 1.51M | 9.14M | 19.00M | 36.84M | 54.80K |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 1.57M |
| Total Liabilities | 2.47M | 2.47M | 7.69M | 3.09M | 2.09M | 4.68M |
| Stockholders Equity | -913.76K | -913.76K | 1.93M | 16.58M | 37.48M | -4.22M |
Cash Flow | ||||||
| Free Cash Flow | -16.71M | -16.71B | -9.85M | -17.85M | -14.54M | -1.38M |
| Operating Cash Flow | -16.71M | -16.71B | -9.85M | -17.85M | -14.54M | -1.38M |
| Investing Cash Flow | 0 | 0 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 9.08M | 9.08B | 0 | 0 | 51.33M | 1.40M |
Virpax Pharmaceuticals Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VRPX, the sentiment is Positive. The current price of 0.15 is above the 20-day moving average (MA) of 0.05, above the 50-day MA of 0.03, and compared to the 200-day MA of , indicating a neutral trend. The MACD of 0.04 indicates Negative momentum. The RSI at 99.86 is Negative, neither overbought nor oversold. The STOCH value of 74.87 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VRPX.
Virpax Pharmaceuticals Risk Analysis
Virpax Pharmaceuticals disclosed 70 risk factors in its most recent earnings report. Virpax Pharmaceuticals reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
3 New RisksVirpax Pharmaceuticals Peers Comparison
Overall Rating
- VRPX37Underperform
SCNI37Underperform
Financial Indicators
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| VRPX | Virpax Pharmaceuticals, Inc. | 0.15 | 0.14 | 675.00% | |
| SCNI | Scinai Immunotherapeutics Ltd. Sponsored Adr | 0.47 | -12.23 | -96.29% | |
| ADTX | Aditxt, Inc. | 0.04 | -1406.12 | -100.00% | |
| CERO | Cero Therapeutics Holdings, Inc. | 0.01 | -0.11 | -91.74% | |
| PBM | Psyence Biomedical Ltd. | 3.31 | -15.44 | -82.35% | |
| CDT | Cdt Equity Inc. | 0.07 | -15624.93 | -100.00% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Dec 30, 2025